 |
Supernus Pharmaceuticals Reports First Quarter 2013 Financial Results
May 13, 2013
|
20.2 KB |
|
| |
ROCKVILLE, Md., May 13, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today reported financial results for the three months ended March 31, 2013, and provided an update on key accomplishments to date.
"Oxtellar XRTM continues to impress us with its clinical performance in the mark...
|
|
Supernus Announces First Quarter 2013 Earnings Conference Call and Webcast
May 6, 2013
|
9.1 KB |
|
| |
ROCKVILLE, Md., May 6, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), today announced that the Company expects to report financial results for the quarter ended March 31, 2013 after the market closes on Monday May 13, 2013. Supernus will host a conference call at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to review the ...
|
|
Supernus Announces Closing of $90 Million of 7.50% Convertible Senior Secured Notes Due 2019
May 6, 2013
|
9.1 KB |
|
| |
ROCKVILLE, Md., May 6, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) ("Supernus") announced today the closing of its previously announced private offering of 7.50% Convertible Senior Secured Notes due 2019 (the "Convertible Notes"). Supernus issued $90 million aggregate principal amount of Convertible Notes (which includes $...
|
|
Supernus Prices Offering of $75 Million of 7.50% Convertible Senior Secured Notes Due 2019
Apr 26, 2013
|
11.4 KB |
|
| |
ROCKVILLE, Md, April 26, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) ("Supernus") today announced the pricing of its offering of $75.0 million aggregate principal amount of Convertible Senior Secured Notes due 2019 (the "Convertible Notes") in a private offering under the Securities Act of 1933, as amended (the "Securities...
|
|
Supernus Announces Proposed Offering of $75 Million of Convertible Senior Secured Notes
Apr 24, 2013
|
8.8 KB |
|
| |
ROCKVILLE, Md., April 24, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) ("Supernus") today announced that it intends to offer, subject to market and other considerations, $75.0 million aggregate principal amount of Convertible Senior Notes due 2019 (the "Convertible Notes") in a private offering. Supernus also intends to gra...
|
|
Supernus Pharmaceuticals Reports Fourth Quarter 2012 and Full Year 2012 Financial Results
Mar 14, 2013
|
22.5 KB |
|
| |
ROCKVILLE, Md., March 14, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today reported financial results for the three and twelve months ended December 31, 2012, and provided an update on key accomplishments to date.
Successfully transitioned from a development stage private...
|
|
Supernus Announces Year-End and Fourth Quarter 2012 Earnings Conference Call and Webcast
Mar 7, 2013
|
9.1 KB |
|
| |
ROCKVILLE, Md., March 7, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), today announced that the Company expects to report the quarter and year ending December 31, 2012 financial results after the market closes on Thursday, March 14, 2013. Supernus will host a conference call at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time...
|
|
Supernus Launches Oxtellar XR(TM) in the United States
Feb 1, 2013
|
11.4 KB |
|
| |
ROCKVILLE, Md., Feb. 1, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today announced that Oxtellar XR tablets are now available for sale in the US. Oxtellar XR is a novel once-daily extended release antiepileptic drug indicated for adjunctive therapy in the treatment of partial seizures ...
|
|
Supernus Appoints Victor Vaughn as Senior Vice President of Sales
Jan 14, 2013
|
11.4 KB |
|
| |
ROCKVILLE, Md., Jan. 14, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today announced the appointment of Victor Vaughn to the position of Senior Vice President of Sales. Mr. Vaughn will be responsible for leading all of the company's sales activities.
"Victor has an outstanding t...
|
|
Supernus Announces Pricing of Public Offering
Nov 29, 2012
|
10.5 KB |
|
| |
ROCKVILLE, Md., Nov. 29, 2012 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company announced the pricing of the underwritten public offering of 6,000,000 shares of its common stock at a price to the public of $8.00 per share. Supernus has granted the underwriters a 30-day option to purchase up to 900,...
|
|
Supernus Announces Positive Phase IIb Results on SPN-810 and Decision to Advance to Late Stage Development
Nov 20, 2012
|
13.7 KB |
|
| |
ROCKVILLE, Md., Nov. 20, 2012 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, received positive topline results from its Phase IIb study on SPN-810 for the treatment of impulsive aggression in ADHD patients.
The study is a multicenter randomized, double-blind, placebo controlled clinical...
|
|
Supernus Receives Three Years of Market Exclusivity for Oxtellar XR(TM)
Nov 19, 2012
|
8.5 KB |
|
| |
ROCKVILLE, Md., Nov. 19, 2012 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, announced today that it has received confirmation from the Food and Drug Administration (the "FDA") that Oxtellar XR has been granted three years of market exclusivity. Supernus received approval from the FDA on Octobe...
|
|
Supernus Pharmaceuticals Reports Third Quarter 2012 Financial Results
Nov 7, 2012
|
17.4 KB |
|
| |
ROCKVILLE, Md., Nov. 7, 2012 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, reported in the November 2, 2012 filing of the Form 10-Q consolidated financial results for the three and nine months ended September 30, 2012, and provided an update on key accomplishments to date.
Third quarte...
|
|
Supernus Announces Issuance of Two Patents Covering Trokendi XR(TM)
Nov 5, 2012
|
35.9 KB |
|
| |
ROCKVILLE, Md., Nov. 5, 2012 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today announced the issuance of two patents (8,298,576 and 8,298,580) by the US Patent and Trademark Office (USPTO) covering Trokendi XR™, its novel once-daily extended-release topiramate product. Both patents wer...
|
|
Supernus Announces Resignation of Board Member
Oct 31, 2012
|
8.7 KB |
|
| |
ROCKVILLE, Md., Oct. 31, 2012 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, announced today that Michael Sheffery, a General Partner at OrbiMed Advisors, LLC has resigned from the company's board of directors, effective October 29, 2012.
"OrbiMed Advisors, LLC remains a significant sha...
|
|
Supernus Receives FDA Approval for Oxtellar XR(TM) in Epilepsy
Oct 22, 2012
|
11.8 KB |
|
| |
ROCKVILLE, Md., Oct. 22, 2012 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, received approval from the Food & Drug Administration (the "FDA") for Oxtellar XR , a novel once-daily extended release formulation of oxcarbazepine (formerly known as SPN-804).
The approval letter states that ...
|
|
Supernus to Present at Two Investor Conferences in September 2012
Aug 29, 2012
|
9.4 KB |
|
| |
ROCKVILLE, Md., Aug. 29, 2012 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today announced that the company's management will present an overview of the company at the following investor conferences in September:
Stifel Nicolaus 2012 Healthcare Conference
...
|
|
Supernus Pharmaceuticals Reports Second Quarter 2012 Financial Results
Aug 10, 2012
|
17.3 KB |
|
| |
ROCKVILLE, Md., Aug. 10, 2012 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today reported consolidated financial results for the three and six months ending June 30, 2012, and provided an update on key accomplishments to date and expected milestones for 2012.
Jack A. Khattar, Presiden...
|
|
Supernus Appoints Dr. Stefan Schwabe, MD, PhD as Exec. VP R&D and Chief Medical Officer
Jul 20, 2012
|
10.7 KB |
|
| |
ROCKVILLE, Md., July 20, 2012 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) today announced that Dr. Stefan Schwabe MD, PhD has joined the Company as Executive Vice President of Research and Development and Chief Medical Officer. In this role, Dr. Schwabe will be responsible for product development activities including Clinical, ...
|
|
Supernus Provides Update on the Launch of Its Two Epilepsy Products Trokendi XR(TM) and SPN-804
Jul 13, 2012
|
11.9 KB |
|
| |
ROCKVILLE, Md., July 13, 2012 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceuticals company, announced on June 26 that it received a tentative approval letter from the Food & Drug Administration (the "FDA") for Trokendi XR™, a once-daily extended release formulation of topiramate (formerly known as SPN-...
|
|
|
This website contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, those statements regarding the company's future financial position, business strategy, budgets, projected costs, plans and objectives of management for future operations. Forward-looking statements contain uncertainties, and may turn out to be materially different. Please see the company's risk factors enumerated in its filings with the Securities and Exchange Commission.
Shareholder Briefcase
Printed Materials
Email Alerts
Download Library
Snapshot
Email
Print Page
Share This
Delicious
Digg
Facebook
LinkedIn
Twitter
RSS Feeds